After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while also moving ahead with a preclinical small molecule for more cancers.

Lytix Biopharma A/S granted Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) exclusive, worldwide rights to oncolytic peptide LTX-315 for dermatologic oncology, excluding metastatic melanoma and metastatic Merkel cell carcinoma. Lytix is to receive $2.5 million in upfront and near-term milestone payments, and is eligible for a further $111 million in milestones, plus royalties...